Literature DB >> 21317559

Ovarian cancer stem cells and inflammation.

Gil Mor1, Gang Yin, Ilana Chefetz, Yang Yang, Ayesha Alvero.   

Abstract

Epithelial ovarian cancer (EOC) is the fourth leading cause of cancer-related deaths in women in the United States and the leading cause of gynecologic cancer deaths. The major limiting factor in the treatment of ovarian cancer is recurrence and chemoresistance. Individuals who succumb to advanced-stage ovarian cancer inevitably become refractory to chemotherapy, resulting in disease progression and death. The source of recurrence and lack of response to chemotherapy is unknown. The focus of this review is to evaluate the question of recurrence and chemoresistance based on the concept of the cancer stem cells and inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21317559      PMCID: PMC3100563          DOI: 10.4161/cbt.11.8.14967

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  51 in total

Review 1.  Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay.

Authors:  George Z Cheng; Weizhou Zhang; Lu-Hai Wang
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

Review 2.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.

Authors:  Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Rev Cancer       Date:  2008-09-11       Impact factor: 60.716

Review 3.  A twist of insight - the role of Twist-family bHLH factors in development.

Authors:  Ralston M Barnes; Anthony B Firulli
Journal:  Int J Dev Biol       Date:  2009       Impact factor: 2.203

4.  Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells.

Authors:  R Chen; A B Alvero; D A Silasi; M G Kelly; S Fest; I Visintin; A Leiser; P E Schwartz; T Rutherford; G Mor
Journal:  Oncogene       Date:  2008-04-14       Impact factor: 9.867

Review 5.  Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells.

Authors:  R Chen; A B Alvero; D-A Silasi; K D Steffensen; G Mor
Journal:  Oncogene       Date:  2008-01-07       Impact factor: 9.867

6.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors.

Authors:  Shu Zhang; Curt Balch; Michael W Chan; Hung-Cheng Lai; Daniela Matei; Jeanne M Schilder; Pearlly S Yan; Tim H-M Huang; Kenneth P Nephew
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

7.  Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.

Authors:  Ayesha B Alvero; Rui Chen; Han-Hsuan Fu; Michele Montagna; Peter E Schwartz; Thomas Rutherford; Dan-Arin Silasi; Karina D Steffensen; Marianne Waldstrom; Irene Visintin; Gil Mor
Journal:  Cell Cycle       Date:  2009-01-01       Impact factor: 4.534

8.  Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products.

Authors:  Sung-Hyung Lee; Bangxing Hong; Andrew Sharabi; Xue F Huang; Si-Yi Chen
Journal:  Stem Cells       Date:  2009-07       Impact factor: 6.277

9.  KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.

Authors:  Ki Hyung Kim; Yanhua Xie; Ewan M Tytler; Richard Woessner; Gil Mor; Ayesha B Alvero
Journal:  J Transl Med       Date:  2009-07-20       Impact factor: 5.531

10.  Twist-1 regulates the miR-199a/214 cluster during development.

Authors:  Youn-Bok Lee; Ioannis Bantounas; Do-Young Lee; Leonidas Phylactou; Maeve A Caldwell; James B Uney
Journal:  Nucleic Acids Res       Date:  2008-11-23       Impact factor: 16.971

View more
  23 in total

1.  The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients.

Authors:  Jiabo Di; Tjitske Duiveman-de Boer; Petra L M Zusterzeel; Carl G Figdor; Leon F A G Massuger; Ruurd Torensma
Journal:  Cell Oncol (Dordr)       Date:  2013-08-09       Impact factor: 6.730

Review 2.  Targeted cancer therapy--are the days of systemic chemotherapy numbered?

Authors:  Won Duk Joo; Irene Visintin; Gil Mor
Journal:  Maturitas       Date:  2013-09-20       Impact factor: 4.342

3.  Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype.

Authors:  Ayesha B Alvero; Michele K Montagna; Vinicius Craveiro; Lanzhen Liu; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2011-09-14       Impact factor: 3.886

4.  Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer.

Authors:  Andrea M Patterson; Saghar Kaabinejadian; Curtis P McMurtrey; Wilfried Bardet; Ken W Jackson; Rosemary E Zuna; Sanam Husain; Gregory P Adams; Glen MacDonald; Rachelle L Dillon; Harold Ames; Rico Buchli; Oriana E Hawkins; Jon A Weidanz; William H Hildebrand
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

5.  Techniques for following labeled cells in vivo: use of X/Y FISH, techniques to optimize fluorescent detection, and beta-galactosidase detection.

Authors:  Michael Craig; Michael Schumacher; Yana Zavros
Journal:  Methods Mol Biol       Date:  2012

6.  Biological characteristics of CD133(+) cancer stem cells derived from human laryngeal carcinoma cell line.

Authors:  Xudong Wei; Jingyu Wang; Jian He; Bingjuan Ma; Jing Chen
Journal:  Int J Clin Exp Med       Date:  2014-09-15

7.  VAV3 Overexpressed in Cancer Stem Cells Is a Poor Prognostic Indicator in Ovarian Cancer Patients.

Authors:  Ah-Young Kwon; Gwang-Il Kim; Ju-Yeon Jeong; Ji-Ye Song; Kyu-Beom Kwack; Chan Lee; Hae-Youn Kang; Tae-Heon Kim; Jin-Hyung Heo; Hee Jung An
Journal:  Stem Cells Dev       Date:  2015-04-09       Impact factor: 3.272

8.  Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.

Authors:  Jacek R Wilczyński; Marek Nowak
Journal:  Exp Suppl       Date:  2022

9.  TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.

Authors:  Ilana Chefetz; Ayesha B Alvero; Jennie C Holmberg; Noah Lebowitz; Vinicius Craveiro; Yang Yang-Hartwich; Gang Yin; Lisa Squillace; Marta Gurrea Soteras; Paulomi Aldo; Gil Mor
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

10.  High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.

Authors:  Ming Liu; Gil Mor; Huan Cheng; Xue Xiang; Pei Hui; Thomas Rutherford; Gang Yin; David L Rimm; Jennie Holmberg; Ayesha Alvero; Dan-Arin Silasi
Journal:  Reprod Sci       Date:  2012-11-20       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.